Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Boston Scientific

Johnson & Johnson reaches $300m settlement over pelvic mesh implants

Settlement of two Australian class actions is largest in country’s history and subject to federal court approval

The Guardian - AU

Coinbase Global, T-Mobile US And 2 Other Stocks Insiders Are Selling

U.S. crude oil futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Accenture And 3 Other Stocks Insiders Are Selling

Johnson & Johnson (NYSE: JNJ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Boston Scientific to pay $105m to Australian women who received pelvic mesh implants

Lawyer says settlement will provide compensation for women who suffered pain and complications from pelvic mesh

The Guardian - AU

How Is The Market Feeling About Boston Scientific?

Boston Scientific's (NYSE:BSX) short percent of float has risen 25.0% since its last report. The company recently reported that it has 19.02 million shares sold short, which is 1.35% of all regular shares that are available for trading.

Benzinga

Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 20.68%. Currently, Boston Scientific has a market capitalization of $54.31 billion.

Benzinga

5 Analysts Have This to Say About Boston Scientific

Over the past 3 months, 5 analysts have published their opinion on Boston Scientific (NYSE:BSX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Boston Scientific Buys Substantial Stake In Korean MedTech Player

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures. The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…

Benzinga

Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.09% on an annualized basis producing an average annual return of 20.41%. Currently, Boston Scientific has a market capitalization of $53.12 billion.

Benzinga

Peering Into Boston Scientific's Recent Short Interest

Boston Scientific's (NYSE:BSX) short percent of float has risen 20.45% since its last report. The company recently reported that it has 15.00 million shares sold short, which is 1.06% of all regular shares that are available for trading.

Benzinga

Where Boston Scientific Stands With Analysts

Boston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter:

Benzinga

If You Invested $1000 In Boston Scientific 10 Years Ago, Here's How Much You Would Have Today

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.68% on an annualized basis producing an average annual return of 21.79%. Currently, Boston Scientific has a market capitalization of $58.91 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2022

Upgrades

Benzinga

This Foreboding Sign Looms Over Boston Scientific's Chart

If history is any guide, there may be trouble ahead for shares of Boston Scientific (NYSE:BSX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

5 Analysts Have This to Say About Boston Scientific

Boston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter:

Benzinga

Boston Scientific Jumps On Upbeat Q2, FY22 Guidance

Boston Scientific Corp (NYSE:BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%. The Company achieved…

Benzinga

Recap: Boston Scientific Q1 Earnings

Boston Scientific (NYSE:BSX) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Boston Scientific reported in-line EPS of $0.39 versus an estimate of $0.39.

Benzinga

Hopeful Golden Cross Forms On Boston Scientific's Chart

If history is any guide, there may be good fortune ahead for shares of Boston Scientific (NYSE:BSX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What 5 Analyst Ratings Have To Say About Boston Scientific

Benzinga

Why Is Boston Scientific Stock Trading Lower Premarket Today?

Boston Scientific Corp (NYSE: BSX) generated

Benzinga

Boston Scientific: Q4 Earnings Insights

Boston Scientific (NYSE:BSX) reported its Q4 earnings results on Wednesday, February 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

What Does Boston Scientific's Debt Look Like?

Over the past three months, shares of Boston Scientific (NYSE:BSX) increased by 0.05%. Before we understand the importance of debt, let us look at how much debt Boston Scientific has.

1 2 3

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.